Conneqt Health Limited · ASX:CQT
Conneqt Health — Investor Presentation (May 2025)
39 slides from Conneqt Health's investor presentation, May 30, 2025
Slide 1: Unlocking Cardiovascular Risk with Arterial Intelligence™
Unlocking Cardiovascular Risk with Arterial Intelligence™ Next-Gen Vascular Biomarkers & Cardiovascular Health Insights C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 2: Management Team
Management Team Total Global Staff: 41 42% Craig R. Cooper Niall Cairns Dr. Sanjeev Bhavnani Catherine Liao, MBA MSC Scott Finneran CEO & Co-Founder Executive Chairman & Co-Founder Medical Officer – Cardiology Chief Strategy & Commercial Officer VP of Engineering Boost Mobile Kestrel Capital Scripps
Slide 3: Equity Raising Details
Equity Raising Details
Slide 4: Equity Raising Overview
Equity Raising Overview TRANSATION DETAILS Offer to raise approximately A$6.5 million via the issue of approximately 162.8 million new fully paid ordinary shares (“New Shares”), comprising of: • A placement to raise approximately A$2.4 via the issue of approximately 61.0 million New Shares in accord
Slide 5: Indicative Timetable
Indicative Timetable INDICATIVE TIMETABLE Trading Halt Wednesday, 28 May 2025 Placement Opens Wednesday, 28 May 2025 Placement Closes (4.00pm AEST) Thursday, 29 May 2025 Announcement of the Offer Friday, 30 May 2025 Trading Halt lifted and CDX shares recommence trading Friday, 30 May 2025 Ex-Entitle
Slide 6: Pro Forma Capital Structure & Use Of Funds
Pro Forma Capital Structure & Use Of Funds USE OF PROCEEDS1 Amount (A$) CAPITAL STRUCTURE Shares (#) Inventory $1.0 million Existing Shares on Issue 406,063,872 Sales & Marketing $1.5 million New Shares under Placement ( 7.1 Placement Capacity) 60,909,580 Product development & regulatory $1.0 millio
Slide 7: Key Risks
Key Risks
Slide 8: Key Risks
Key Risks Activities in the Company and its controlled entities, as in any business, are subject to risks, which may impact on the Company's future performance. The Company and its controlled entities have implemented appropriate strategies, actions, systems and safeguards for known risks, however,
Slide 9: Key Risks
Key Risks Principal Risks Continued: International trade and tariffs The Company operates globally, with suppliers, customers, and operations spread across multiple countries. Changes to international trade arrangements, including tariffs, duties, and customs inspection procedures, may adversely imp
Slide 10: Key Risks
Key Risks Principal Risks Continued: Profitability The Company incurred operating losses each year since our inception in 1994, and may continue to incur net losses in the future. The Company expects its operating expenses to increase in the future as the Company grows its business. These efforts an
Slide 11: Further Information
Further Information General Risks: Economic risks General economic conditions, introduction of tax reform, new legislation, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company’s business activities and potential exploration and development
Slide 12: Further Information
Further Information General Risks Continued: Underwriting Risk The Company has entered into an underwriting agreement (Underwriting Agreement) with Blackpeak Capital (the Underwriter) pursuant to which the Underwriter has agreed to underwrite the Entitlement Offer subject to terms and conditions of
Slide 13: Extra Risks to Consider
Extra Risks to Consider Difficulties encountered with early commercialisation of new technology There are a number of risks associated with the early commercialisation of new technology, including an inherent risk of failure, and the possibility that the products developed by the Company may fail to
Slide 14: International Offer Restrictions
International Offer Restrictions
Slide 15: International Offer Restrictions
International Offer Restrictions This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any
Slide 16: Underwriting Agreement Termination Events
Underwriting Agreement Termination Events
Slide 17: Underwriting Agreement Termination Events
Underwriting Agreement Termination Events Blackpeak Capital Pty Ltd (the Underwriter) may terminate the Underwriting Agreement (and be released from its underwriting obligations) without cost or liability on the occurrence of certain termination events including: Part A - Events not subject to 'mate
Slide 18: Underwriting Agreement Termination Events
Underwriting Agreement Termination Events The Underwriter may terminate the Underwriting Agreement (and be released from its underwriting obligations) without cost or liability on the occurrence of certain termination events including: Part A - Events not subject to 'materiality’ continued: • (Timet
Slide 19: Underwriting Agreement Termination Events
Underwriting Agreement Termination Events The Underwriter may terminate the Underwriting Agreement (and be released from its underwriting obligations) without cost or liability on the occurrence of certain termination events including: Part B - Events subject to ‘materiality’ : • (future matters) An
Slide 20: Underwriting Agreement Termination Events
Underwriting Agreement Termination Events The Underwriter may terminate the Underwriting Agreement (and be released from its underwriting obligations) without cost or liability on the occurrence of certain termination events including: Part B - Events subject to 'materiality’ continued: • (hostiliti
Slide 21: Opportunity Snapshot
Opportunity Snapshot Strong revenue Capital raise to Opportunity to growth driven accelerate claim category by multiple new commercial Targeting a ownership in products and growth, product Pioneering $430 billion noninvasive entry to new pipeline, and ASX listed arterial health market vascular healt
Slide 22: Arterial Health - The World's Largest Category Ownership Opportunity
Arterial Health - The World's Largest Category Ownership Opportunity Metabolic Health (US $450m)* Blood Biomarkers (US $1.2B)* Performance Fitness (US $3.8B)* Sleep (US $5.2B)* Pulse Oximetry (US $9B)* Arterial Health (US $???) C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S * Curren
Slide 23: Targeting the World's Largest Health Problems
Targeting the Total Cost of Cardiovascular Disease (CVD) Annually* World’s Largest Health Problems $363B $1.1 Trillion 2020 2035 Cardiovascular (CV) #1 disease is the 113M 19M Hypertensives in the USA Heart Disease Deaths Globally (50% of US Adults) (1 Every 36 Seconds in USA) Killer of humans globa
Slide 24: Cardiovascular Disease is a $430B Market
Cardiovascular Disease is a $430B Market $207 billion 1 $118 billion 2 Pharmaceuticals Medical Procedures $86 billion 3 $19 billion 4 Medical Devices Supplements 1 https://www.biospace.com/press-releases/cardiovascular-drugs-market-size-to-worth-usd-207-78-billion-by-2033 2 https://www.biospace.com/
Slide 25: We Measure Risk of Cardiovascular Disease in Order to Guide Treatment & Lifestyle Decisions
We Measure Risk of Cardiovascular Disease in Order to Guide Treatment & Lifestyle Decisions “What is [ my ] risk of heart attack & stroke, and what to do?” C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 26: Cardiex Quantifies Heart Risk with Vascular Biomarkers
Cardiex Quantifies Heart Risk with Vascular Biomarkers Biomarker Measurement is Heart Risk Central Blood Below Threshold Pressure High 2–3 times greater risk of heart Central Pulse attack and stroke Below Threshold Pressure Augmentation Index (AIx) Below Threshold Intermediate Moderately increased r
Slide 27: Our Foundational Technology: SphygmoCor Central Pulse Wave Analysis
Our Foundational Technology: SphygmoCor Central Pulse Wave Analysis ® Gold Standard in Arterial Technology Proprietary Clinically Validated Health Monitoring Pioneer (2002) Technology & IP & Trusted *Only FDA cleared devices for full arterial UNIQUE CPT Code: 93050 waveform analysis in adults. 23 Pa
Slide 28: Validated by Two Decades of Research
Research 23,000+ Citations Validated by Two Decades of Research SphygmoCor® is widely regarded as a reference-standard device for central hemodynamic measurements in cardiovascular research. Numerous studies have confirmed that SphygmoCor’s technology to provide reliable and accurate measurements of
Slide 29: Trusted by the World's Best in Healthcare & Science
Trusted by the World’s Best in Healthcare & Science C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S
Slide 30: Products & Markets
Products & Markets ATCOR Medical SphygmorCor® Clinical Trials & Drug Advanced Cardiovascular XCEL Point-of-Care Development Diagnostics Enhancing drug discovery Empowering healthcare providers with vascular biomarkers to with non-invasive arterial health optimize patient stratification, insights for
Slide 31: Products & Markets
Products & Markets CONNEQT® Health (launched Jan, 2025) Proactive Cardiovascular Wellness CONNEQT Pulse Enabling consumers to take Home use control of their heart health with heart health insights, risk assessments, and science- backed action plans. Enhances clinical interpretation and patient engag
Slide 32: CONNEQT Pulse App
CONNEQT Pulse App 4.3 Revolutionizing Cardiovascular Health Market Gap Our Disruption Business Impact Current BP apps show A device-agnostic platform Subscription-driven static readings, leaving that drives active growth fueled by users as passive engagement with real-time, continuous personalizatio
Slide 33: How We Compare to Patient-Centric Cardiovascular Screenings
How We Compare to Patient-Centric Cardiovascular Screenings Test Price Heart Risk Assessed # of Reports In-Home Test Up to Full-Body MRI Scan None One-Time No $2,500 Detailed coronary artery plaque Cleerly Heart Scan Up to $1,500 One-Time No analysis Coronary Calcium Scan Up to $500 Measures calcium
Slide 34: Growth Spotlight - CONNEQT Arterial Health Assessment Sales to Date
Growth Spotlight - CONNEQT Arterial Health Assessment CONNEQT Arterial Health April May June Unit Sales Assessment Kit (DTC) ~10 ~15 ~30 Run-rate $1.7m $2.7m $5.1m (AUD) COGS ~$60 CAC $28-90 $300 + ~3,000 ASP [Subscription Sales to Date Sales (June (3 months since launch - DTC, 2025)] Pharma, Resear
Slide 35: The Future: Data-Driven Cardiovascular Care
The Future: Data-Driven Cardiovascular Care Powered by “SphygmoCor Biomarker-as-a-Service” (BaaS) Digital health is moving from hardware-based diagnostics to cloud-based insights → AI-driven biomarker extraction enables scalable, device-agnostic health intelligence → Cardiex is leading this transiti
Slide 36: From Hardware Sales to Data Monetization
From Hardware Sales Health Insurers to Data Monetization Health Intelligence Marketplace Data Analytics/Research AI-driven real-world vascular health data for population analytics Subscription-Based API Access Analytics Data Lake Biomarker-as-a- Partners integrate our insights Service (BaaS) into th
Slide 37: Our Unique Market Position with a Deep Moat
Our Unique Market Position with a Deep Moat Growth through new Significant market product development. opportunity in world's largest health category. New product development, Existing technology, unique home assessment validation and service and biomarker as a commercialization. service technology.
Slide 38: How the Market is Aligning with Our Data-Centric Future
How the Market is Aligning with Our Data-Centric Future Acceptance of AI in Health Monitoring. Willingness Demand for to Invest in Personalized Health Health Data. Monitoring. Comfort with At-Home Health Solutions. Increased Adoption of Health- Tracking Devices. C A R D I E X D I G I T A L V A S C U
Slide 39: Thank You!
Thank You! C A R D I E X D I G I T A L V A S C U L A R B I O M A R K E R S